Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright

Key Points

• HC Wainwright reiterated a Buy rating on Capricor with a $60 price target, implying about a 70.07% upside from the prior close.
• Analyst coverage is broadly positive—nine firms rate the stock a Buy and one a Sell—giving an average target of $40.82 and an overall "Moderate Buy" consensus.
• The shares jumped about 15.2% to $35.28 on heavy volume, the company has a market cap of roughly $1.61 billion, and institutional investors (including Vanguard, Suvretta, Tang and RA Capital) have recently increased or initiated positions, with institutions owning ~21.68%.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $60.00 price target on the biotechnology company's stock. HC Wainwright's price target would indicate a potential upside of 70.07% from the company's previous close.

CAPR has been the topic of a number of other research reports. Alliance Global Partners reiterated a "buy" rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. UBS Group set a $50.00 target price on shares of Capricor Therapeutics in a research note on Monday, December 15th. Piper Sandler restated an "overweight" rating and set a $45.00 price target (up from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, January 11th. Finally, B. Riley Financial reissued a "buy" rating and set a $50.00 price objective (up from $21.00) on shares of Capricor Therapeutics in a research note on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $40.82.

Capricor Therapeutics Trading Up 15.2%

Shares of Capricor Therapeutics stock traded up $4.65 during trading hours on Tuesday, reaching $35.28. The stock had a trading volume of 2,454,245 shares, compared to its average volume of 1,258,353. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The stock's 50 day moving average is $25.38 and its 200 day moving average is $15.93. The firm has a market capitalization of $1.61 billion, a PE ratio of -19.60 and a beta of 0.37.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company's stock valued at $73,936,000 after acquiring an additional 355,161 shares during the period. Suvretta Capital Management LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth about $51,533,000. Tang Capital Management LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at about $49,062,000. RA Capital Management L.P. acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $43,516,000. Finally, Geode Capital Management LLC increased its stake in Capricor Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company's stock worth $29,367,000 after buying an additional 55,766 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.